AstraZeneca Acquires Amolyt Pharma for up to $1.05 Billion

AstraZeneca has agreed to buy Amolyt Pharma, a clinical-stage biopharmaceutical company focusing on rare endocrine and related diseases, for a total consideration of up to $1.05 billion. The acquisition deal includes an upfront payment of $800 million and a potential milestone payment of $250 million. Amolyt Pharma, known for its innovative therapeutic peptides, has eneboparatide in Phase 3 trials for hypoparathyroidism and is developing other treatments for rare endocrine diseases.

Thierry Abribat, CEO of Amolyt Pharma, expresses gratitude towards the team's accomplishments and the support from investigators, patients, and associations. He looks forward to the continued development of their portfolio under Alexion, AstraZeneca's rare disease division. Raphaël Wisniewski of Andera Partners highlights Amolyt Pharma's impact on biotech in France and Europe, acknowledging the team's dedication and innovation.

The deal, subject to customary closing conditions and regulatory clearances, is expected to close by the end of the third quarter of 2024. Centerview Partners LLC and Goldman Sachs Bank Europe SE served as financial advisors to Amolyt, with legal counsel from Cooley LLP and Jones Day.